If you’re on the hunt for value stocks to buy, you’ve come to the right place.
In an ode to Ben Graham, arguably the father of investing, I’m going to pull together a list of 10 stocks trading below book value that I believe will appreciate over the next 12 to 24 months.
However, it’s not going to be easy.
I came across an online Barron’s article that discussed the difficulty of buying stocks below book value, as Graham did back in his prime.
Michael Green, portfolio manager at Moody Aldrich Partners “notes that just 6% of New York Stock Exchange companies now trade under book value, versus 25% in March 2000, when the major averages peaked (Green excludes closed-end and bond funds in making this calculation.),” Andrew Bary wrote in 2004.
“Cheap stocks actually were more plentiful during the market bubble than they are now, due to the narrow breadth of the technology-led market advance in 1999 and early 2000. Over the past 75 years, low price-book stocks on the Big Board were most abundant at the historic market bottoms of 1932 and 1975.”
Top 5 Low Price Stocks To Invest In 2023: Aterian, Inc.(ATER)
Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. It provides Artificial Intelligence Mohawk e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. The company's platform provides home and kitchen appliances; kitchenware, heating, cooling, and health and beauty products; and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners under the hOmeLabs, Vremi, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, and Spiralizer brands. It also sells essential oils. The company primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was formerly known as Mohawk Group Holdings, Inc. and changes its name to Aterian, Inc. in April 2021. Aterian, Inc. was founded in 2014 and is headquartered in New York, New York.
Advisors’ Opinion:
- [By Keith Noonan (TMFNoons)]
Shares of Aterian (NASDAQ:ATER) crashed on Tuesday. The e-commerce company saw its valuation surge after emerging as a potential short-squeeze candidate, but big gains over the last couple of weeks also opened the door for a dramatic pullback. The stock ended today’s trading down roughly 39%.
Top 5 Low Price Stocks To Invest In 2023: CTI BioPharma Corp.(CTIC)
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and health care providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis.
PIXUVRI
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Advisors’ Opinion:
- [By Stephan Byrd]
Get a free copy of the Zacks research report on CTI BioPharma (CTIC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Steve Symington]
Nevertheless, several individual stocks failed to keep up. Read on to see why CTI BioPharma (NASDAQ:CTIC), PetMed Express (NASDAQ:PETS), and Pfizer (NYSE:PFE) each slumped today.
- [By Brian Feroldi]
In response to the company sharing a clinical update, shares of CTI BioPharma (NASDAQ:CTIC), a clinical-stage biotech focused on blood-related cancers, fell 13% as of 12:05 p.m. EDT on Monday.
Top 5 Low Price Stocks To Invest In 2023: Pacira Pharmaceuticals, Inc.(PCRX)
Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
EXPAREL
EXPAREL provides postsurgical analgesia and reduces the consumption of opioid medications. The Company is pursuing several additional indications for EXPAREL and submitted the United States Food and Drug Administration supplemental New Drug Application (sNDA) for nerve block administration. It initiated over two nerve block trials comparing the effect of EXPAREL versus placebo through a femoral nerve block study for total knee arthroplasty and a brachial plexus block study for total shoulder arthroplasty or rotator cuff repair procedures. The Company plans to initiate a Phase II trial with patients suffering from chronic lower back pain caused by facet joint dysfunction with EXPAREL as a single dose administration to determine the optimal dose, which will inform a Phase III study design. It plans to initiate EXPAREL study in pediatric patients. In addition, it is initiating a multicenter randomized double-blind placebo controlled study in patients undergoing a unilateral Total Knee Arthroplasty (TKA). It plans to generate Phase IV studies in additional oral and maxillofacial surgeries to provide clinical guidance to the oral and maxillofacial community.
DepoCyt(e)
DepoCyt(e) is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine. DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis, a complication of lymphoma, a cancer of the immune system. DepoCyt(e) is dosed once every two weeks in an outpatient setting.
DepoMeloxicam
The Company’s preclinical product candidate, DepoMLX, is a long-acting non-steroidal anti-inflammatory drug (NSAID) designed to treat moderate to severe acute postsurgical pain as part of a non-opioid multimodal regimen. A product designed for single dose local administration, such as DepoMLX could provide a longer duration of pain relief at a lower concentration of systemic NSAIDs, which are known to cause dose dependent gastrointestinal side effects. Meloxicam is available as an oral formulation.
DepoTranexamic Acid
Tranexamic Acid (TXA) is used off-label as a systemic injection or as a topical application and is used to treat or prevent excessive blood loss during surgery by promoting hemostasis. The formulation of tranexamic acid, however, has a short-lived effect, while the risk of bleeding continues for two to three days after surgery. DepoTXA, a long acting local antifibrinolytic agent combining immediate and extended release TXA, address the unmet need for rapid ambulation and discharge in the ambulatory surgery environment for joint surgery (orthopedic surgery, including spine and trauma procedures and cardiothoracic surgery). DepoTXA is in pre-clinical development.
The Company competes with Halyard Health, Inc.
Advisors’ Opinion:
- [By Joseph Griffin]
Pacira Pharmaceuticals (NASDAQ:PCRX) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.
- [By Ethan Ryder]
Pacira Pharmaceuticals (NASDAQ:PCRX)’s stock had its “overweight” rating reiterated by stock analysts at Piper Jaffray Companies in a report issued on Tuesday, The Fly reports. They currently have a $51.00 price objective on the stock. Piper Jaffray Companies’ target price suggests a potential upside of 12.93% from the company’s current price.
Top 5 Low Price Stocks To Invest In 2023: Infinity Property and Casualty Corporation(IPCC)
Infinity Property and Casualty Corporation, through its subsidiaries, provides personal automobile insurance with a concentration on nonstandard auto insurance in the United States. The company offers personal automobile insurance to individuals; mono-line commercial vehicle insurance to businesses; and classic collector insurance, which provides protection for classic collectible automobiles. It products provide coverage to individuals for liability to others for bodily injury and property damage, and for physical damage to an insured?s own vehicle from collision and various other perils. Infinity distributes its products primarily through a network of independent agencies and brokers. The company was founded in 2002 and is headquartered in Birmingham, Alabama.
Advisors’ Opinion:
- [By Stephan Byrd]
Infinity Property and Casualty (NASDAQ:IPCC) and Hartford Financial Services Group (NYSE:HIG) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
- [By Shane Hupp]
Berkshire Hathaway Inc. Class B (NYSE: BRK.B) and Infinity Property and Casualty (NASDAQ:IPCC) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.
- [By Joseph Griffin]
ValuEngine lowered shares of Infinity Property and Casualty (NASDAQ:IPCC) from a strong-buy rating to a buy rating in a research report released on Saturday morning.
Top 5 Low Price Stocks To Invest In 2023: Village Super Market Inc.(VLGEA)
Village Super Market, Inc., together with its subsidiaries, operates a chain of supermarkets in the United States. The company?s superstores feature specialty departments, such as home meal replacement, on-site bakery, and expanded delicatessen that includes prepared food, natural and organic food, ethnic and international food, seafood sections, as well as pharmacies and salad bars. Its superstores also offer non-food items, including cut flowers, health and beauty aids, greeting cards, and small appliances. As of December 16, 2011, the company operated a chain of 28 supermarkets under the ShopRite name in New Jersey, Maryland, and eastern Pennsylvania. Village Super Market, Inc. was founded in 1933 and is based in Springfield, New Jersey.
Advisors’ Opinion:
- [By David Jagielski (tmfdjagielski)]
Scotts Miracle-Gro (NYSE:SMG), Village Super Market (NASDAQ:VLGEA), and AT&T (NYSE:T) have all been falling this year. And they all pay better than the 1.3% yield you can expect from the average stock in the S&P 500.
- [By Shane Hupp]
BidaskClub upgraded shares of Village Super Market (NASDAQ:VLGEA) from a sell rating to a hold rating in a research report report published on Tuesday.
- [By Ethan Ryder]
BidaskClub lowered shares of Village Super Market (NASDAQ:VLGEA) from a hold rating to a sell rating in a report published on Tuesday.
Shares of VLGEA stock opened at $27.20 on Tuesday. Village Super Market has a 52-week low of $21.95 and a 52-week high of $31.49. The company has a quick ratio of 1.38, a current ratio of 1.81 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $392.70 million, a price-to-earnings ratio of 13.80 and a beta of 0.04.
- [By Joseph Griffin]
Media stories about Village Super Market, Inc. Class A (NASDAQ:VLGEA) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Village Super Market, Inc. Class A earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 43.9608995956738 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
.jpg)
